Test Price
2,800 AED✅ Home Collection Available
SGSH Gene Mucopolysaccharidosis Type IIIA (Sanfilippo A Syndrome) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين SGSH للكشف عن داء عديد السكاريد المخاطي النوع الثالث أ (متلازمة سانفيليبو أ) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي 2026
Clinical Executive Summary
✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing (Cert: INT/EGQ/2509DA/3139).
✓ Premium Logistics: Hospital-Grade Home Collection via ISO Certified Cold-Chain Protocol and VIP Mobile Phlebotomy (8 AM – 11 PM daily).
✓ Clinical Guidance: Telephonic Post-Test Clinical Interpretation by DHA-Licensed Clinical Geneticist included.
✓ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
يقدم هذا التحليل الجيني المتقدم تقنية التسلسل الجيني من الجيل التالي (NGS) للكشف عن الطفرات الممرضة في جين SGSH المرتبط بداء عديد السكاريد المخاطي النوع الثالث أ (متلازمة سانفيليبو أ). يتم تنفيذ التحليل وفقاً لمعايير الآيزو 9001:2015 وتحت إشراف هيئة الصحة بدبي (DHA)، مع خدمة سحب عينات منزلية معتمدة بسلسلة تبريد دقيقة. النتائج متاحة خلال 3 إلى 4 أسابيع مع استشارة وراثية متكاملة بعد الفحص لتفسير النتائج وتوجيه الخطط العلاجية.
Overview
The SGSH Gene NGS Test is a high-resolution genetic analysis that screens for pathogenic variants in the N-sulfoglucosamine sulfohydrolase (SGSH) gene, the causative locus for Mucopolysaccharidosis Type IIIA (Sanfilippo A Syndrome) — a rare autosomal recessive lysosomal storage disorder. يكشف هذا الفحص الجيني عن الطفرات المسببة لداء سانفيليبو أ بدقة تشخيصية عالية. This test is indicated for pediatric patients presenting with progressive neurodegeneration, behavioral disturbances, and coarse facial features, as well as for carrier screening and family planning purposes.
| Feature | Our Test (NGS – SGSH Full Gene) | Closest Alternative (Enzyme Assay) |
|---|---|---|
| Diagnostic Precision | Single-nucleotide resolution; detects missense, nonsense, splice-site, indel, and copy-number variants | Measures heparan N-sulfatase enzyme activity only; cannot identify specific mutation type |
| Methodology | Next Generation Sequencing (NGS) with Sanger confirmation of all pathogenic calls | Fluorometric enzyme activity assay in leukocytes or cultured fibroblasts |
| Turnaround Time | 3 to 4 Weeks | 4 to 8 Weeks (often requires skin biopsy for fibroblast culture) |
| Carrier Screening Utility | ✓ Definitive carrier status determination | Limited; reduced enzyme activity may overlap with normal range |
| Sample Requirement | Blood, Extracted DNA, or One Drop Blood on FTA Card | Fresh whole blood or skin biopsy (invasive) |
Physician Insight & Safety Protocol
Dr. PRABHAKAR REDDY
DHA License: 61713011 | Consultant Clinical Geneticist
As a clinician who has managed numerous families affected by Mucopolysaccharidosis Type IIIA across the UAE, I emphasize that this NGS-based SGSH gene test provides definitive molecular confirmation, but results must always be interpreted in the context of the patient's complete clinical picture. A negative NGS result does not entirely exclude MPS IIIA if clinical suspicion remains high — additional biochemical testing or whole-exome sequencing may be warranted. Above all, please do not discontinue any prescribed medication or enzyme replacement therapy without consulting your treating physician, as abrupt cessation can precipitate acute metabolic decompensation.
⚠ Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do NOT proceed with sample collection if any apply):
- Active febrile illness or systemic infection (postpone until fully recovered for at least 7 days)
- Current anticoagulant therapy (e.g., Warfarin, Heparin, Enoxaparin) without prior physician clearance
- Severe thrombocytopenia (platelet count below 50,000/µL) or active bleeding disorder
- Known hypersensitivity to phlebotomy site antiseptics (chlorhexidine or povidone-iodine)
- Patient is a minor (<18 years) and informed consent from a legal guardian has not been obtained — mandatory under UAE CDS Law 2026
Emergency Red Flags — Seek Immediate Medical Attention:
- Sudden loss of developmental milestones (e.g., loss of speech, loss of ambulation) in a child under evaluation
- Acute behavioral crisis with self-injurious behavior or severe aggression
- Signs of raised intracranial pressure: early morning headaches, projectile vomiting, sunsetting eyes
- Seizure activity or status epilepticus
- Respiratory distress or stridor suggestive of airway obstruction
⚠ Medication Warning:
Do not discontinue prescribed medication without consulting your doctor. Patients on enzyme replacement therapy, anticonvulsants, or behavioral medications must maintain their current regimen unless a physician explicitly advises otherwise. Abrupt medication changes in MPS IIIA patients can trigger severe neurological deterioration.
Pre-Test Preparation & Genetic Counseling
Prior to sample collection, the following preparatory steps are required to ensure diagnostic accuracy and regulatory compliance:
- Mandatory Genetic Counseling Session: A DHA-licensed genetic counselor will conduct a comprehensive pre-test consultation to draw a detailed pedigree chart documenting all family members affected with Mucopolysaccharidosis Type IIIA or related lysosomal storage disorders. This session is essential for accurate risk stratification and result interpretation.
- Clinical History Documentation: The referring physician must provide a complete clinical history including age of symptom onset, neurodevelopmental regression pattern, prior biochemical or imaging findings, and any existing enzyme assay results.
- Informed Consent: Written informed consent must be obtained from the patient or legal guardian (mandatory for minors per Federal Decree-Law No. 41 of 2024, Art. 87).
- Fasting: No fasting is required for this genetic test. Patients may eat and drink normally before sample collection.
Patient FAQ & Clinical Guidance
1. What is the SGSH gene test, and why is it performed for suspected Sanfilippo A syndrome?
The SGSH gene NGS test is a high-resolution genetic diagnostic tool that sequences the entire coding region of the N-sulfoglucosamine sulfohydrolase gene to identify pathogenic mutations responsible for Mucopolysaccharidosis Type IIIA, enabling definitive molecular confirmation when clinical symptoms such as progressive neurodegeneration, sleep disturbances, and coarse facies raise suspicion. This test also facilitates accurate carrier screening for at-risk family members, prenatal diagnosis in future pregnancies, and genotype-phenotype correlation that may guide emerging targeted therapies currently in clinical trials.
ما هو تحليل جين SGSH ولماذا يتم إجراؤه؟ تحليل جين SGSH هو فحص جيني تشخيصي عالي الدقة يستخدم تقنية التسلسل الجيني من الجيل التالي (NGS) لتحديد الطفرات الممرضة في جين سلفوهيدرولاز الغلوكوزامين المسؤولة عن داء عديد السكاريد المخاطي النوع الثالث أ (متلازمة سانفيليبو أ). يُجرى هذا التحليل لتأكيد التشخيص لدى المرضى الذين تظهر عليهم أعراض تنكس عصبي تدريجي واضطرابات سلوكية، وكذلك لفحص حاملي المرض بين أفراد الأسرة.
2. How should I prepare for this genetic test, and what sample types are accepted?
Preparation for the SGSH gene NGS test requires a mandatory pre-test genetic counseling session to construct a detailed family pedigree, completion of informed consent documentation, and provision of a complete clinical history from your referring physician, while the accepted sample types include whole blood collected in EDTA tubes, previously extracted DNA at appropriate concentration, or a single drop of blood dried on an FTA card for convenient home collection. No fasting or medication adjustments are required prior to sample collection unless specifically directed by your physician.
كيف أستعد لهذا التحليل الجيني وما هي أنواع العينات المقبولة؟ يتطلب التحضير جلسة استشارة وراثية إلزامية قبل الفحص لرسم مخطط النسب العائلي وتوثيق التاريخ الطبي الكامل. أنواع العينات المقبولة تشمل: الدم الكامل في أنابيب EDTA، أو الحمض النووي المستخلص مسبقاً، أو نقطة دم واحدة على بطاقة FTA. لا يشترط الصيام قبل جمع العينة.
3. What do my results mean, and what are the next steps after receiving a positive result?
A positive result indicates the identification of one or two pathogenic SGSH variants confirming a diagnosis of Mucopolysaccharidosis Type IIIA or carrier status respectively, after which your DHA-licensed clinical geneticist will provide a comprehensive post-test consultation to explain the molecular findings, discuss implications for family members who may also be at risk, and coordinate with your treating pediatrician or metabolic specialist to establish a multidisciplinary management plan encompassing developmental support, seizure control, and nutritional optimization. Referral to specialized centers offering clinical trials for emerging therapies such as intrathecal enzyme replacement or gene therapy may also be discussed if applicable.
ماذا تعني نتائج التحليل وما هي الخطوات التالية بعد الحصول على نتيجة إيجابية؟ النتيجة الإيجابية تؤكد وجود طفرة أو طفرتين ممرضتين في جين SGSH مما يثبت تشخيص داء سانفيليبو أ أو حالة الحمل الجيني. بعد ذلك، سيقدم أخصائي الوراثة السريرية استشارة شاملة بعد الفحص لشرح النتائج الجزيئية ومناقشة الآثار المترتبة على أفراد الأسرة المعرضين للخطر، وتنسيق خطة رعاية متعددة التخصصات تشمل الدعم النمائي والتحكم في النوبات.
UAE Regulatory Compliance & Legal Mandates
- Federal Decree-Law No. 41 of 2024 (Art. 87): This facility strictly adheres to all provisions governing genetic testing, informed consent, and confidentiality of genomic data as mandated by UAE federal law.
- CDS Law 2026 (Minors): Genetic testing of minors requires documented informed consent from a legal guardian. Pre- genetic counseling is mandatory for all pediatric patients.
- UAE PDPL (Personal Data Protection Law): All genomic and personal health data is processed, stored, and transmitted in full compliance with UAE data privacy regulations. Patient data is never shared with third parties without explicit written consent.
- ISO 9001:2015 Certification: Facility certification number INT/EGQ/2509DA/3139, ensuring internationally recognized quality management standards across all laboratory processes.
- DHA Facility License: 9834453 — Licensed and audited by the Dubai Health Authority.
Home Collection & Contact
VIP Mobile Phlebotomy Service: ISO Certified Cold-Chain Home Collection available daily from 8:00 AM to 11:00 PM across all Emirates. A DHA-licensed phlebotomist arrives at your location with full cold-chain transport equipment.
WhatsApp Support & Insurance Verification: +971 54 548 8731 — Send your insurance card image for direct billing verification before booking.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians